" if any have yet been able to cross the brain blood barrier."
"Roche has claimed the latest phase 2 readout for its multiple sclerosis (MS) drug backs up the BTK inhibitor’s "best in disease" potential by achieving the "holy grail" in biopharma: crossing the blood-brain barrier."
Not relevant to what PAB are doing but looks like they are catching up. Link to article below -
Roche BTK inhibitor may show 'holy grail' of brain penetration (fiercebiotech.com)
Ann: Appendix 4E and 2023 Annual Report, page-22
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $5.395K | 674.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 5603441 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 478105 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.8¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.8¢ | 75272 | ||
| Last updated 14.06pm 09/05/2024 ? | |||||
| PAB (ASX) Chart |